above constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning the Company’s expectations or estimates relating to the restructuring plan, including the anticipated workforce reduction, timing of completion of the restructuring plan, the ability of the Company to manage local employee consultative processes, and timing and amounts of the charges to be recorded and cash expenditures…

Results of Operations and Financial Condition On August 4, 2026, Bio-Rad Laboratories, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report. The information set forth under Item 7.01, Regulation FD Disclosure, concerning the Supplemental Earnings Presentation (as defined therein) is incorporated herein by reference.

Results of Operations and Financial Condition On April 30, 2026, Bio-Rad Laboratories, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report. The information set forth under Item 7.01, Regulation FD Disclosure, concerning the Supplemental Earnings Presentation (as defined therein) is incorporated herein by reference.

Annual board election with no specific departures or appointments mentioned.

Results of Operations and Financial Condition On February 12, 2026, Bio-Rad Laboratories, Inc. (the “Company”) announced its financial results for the quarter ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report. The information set forth under Item 7.01, Regulation FD Disclosure, concerning the Supplemental Earnings Presentation (as defined therein) is incorporated herein by reference.

Results of Operations and Financial Condition On October 29, 2025, Bio-Rad Laboratories, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report. The information set forth under Item 7.01, Regulation FD Disclosure, concerning the Supplemental Earnings Presentation (as defined therein) is incorporated herein by reference.

Results of Operations and Financial Condition On July 31, 2025, Bio-Rad Laboratories, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report. The information set forth under Item 7.01, Regulation FD Disclosure, concerning the Supplemental Earnings Presentation (as defined therein) is incorporated herein by reference.

Executive Vice President — Michael Crowley: The EVP is retiring with a named successor (Rajat Mehta) and a transition period, indicating an orderly succession rather than a sudden loss of leadership.

Other Events. As previously disclosed, on February 13, 2025, Bio-Rad Laboratories, Inc. (the “Company”) announced that it had entered into a binding offer to purchase all of the equity interests of Stilla Technologies, a French corporation (“Stilla”). On June 30, 2025, an affiliate of the Company completed the acquisition of all of the equity interests of Stilla. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be si…

of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in…

of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in…

above constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning the Company’s expectations or estimates relating to the restructuring plan, including the anticipated workforce reduction, timing of completion of the restructuring plan, and timing and amounts of the charge to be recorded and cash expenditures to be made in connection with the restructuring plan. The Company cautions yo…

of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in…

President and Chief Operating Officer — Jonathan P. DiVincenzo: The filing announces the appointment of a new President and COO from an external company, which is a significant executive addition rather than a departure.

Other Events On July 29, 2024, the board of directors of Bio-Rad Laboratories, Inc. (the “Company”) authorized increasing the amount available under the Company's 2023 Share Repurchase Program to allow the Company to repurchase up to an additional $500 million of the Company’s outstanding common stock. As of July 31, 2024, a total of approximately $578 million is available for repurchases under the Company's 2023 Share Repurchase Program. Repurchases under the 2023 Share Repurchase Program ma…

of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in…

of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in…

Executive Vice President and President, Life Science Group — Simon May: The departure of a named executive officer (EVP/President) was immediately filled by an internal promotion, indicating an orderly succession rather than a sudden loss of leadership.

COO — Dr. Andrew Last: The COO is retiring with a planned transition period and search for a successor, indicating an orderly succession rather than a sudden loss.

CFO — Roop K. Lakkaraju: The filing announces the appointment of an external candidate as the new Chief Financial Officer, which is a significant management change but not a departure of a sitting executive.